2021
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonthsAbrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
Kim I, Kim D, Kim S, Singer E, Jang T, Ghodoussipour S, Aron M, Kim I. Abrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation. Journal Of Clinical Oncology 2021, 39: 77-77. DOI: 10.1200/jco.2020.39.28_suppl.77.Peer-Reviewed Original ResearchProstate cancer-specific survivalU.S. Preventive Services Task ForceSurvival disparitiesUninsured patientsSocioeconomic quintileProstate cancerInsurance statusMarital statusWorse prostate cancer-specific survivalProstate cancer screening recommendationsCox proportional hazards modelDiagnostic time periodsCancer-specific survivalCancer screening recommendationsProportional hazards modelProstate-specific antigenScreening recommendationsSurvival outcomesInsured patientsWorse outcomesHazards modelPatientsBetter outcomesMedian household incomeUninsured individuals
2018
Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCombined Modality TherapyDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHumansMaleOutcome Assessment, Health CareProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsAndrogen deprivation therapyAdvanced prostate cancerRadical prostatectomyProstate cancerDeprivation therapyOverall survivalUrinary incontinenceErectile dysfunctionProstate cancer-specific survivalProstate cancer-specific deathCox proportional hazards modelCancer-specific survivalCancer-specific deathKaplan-Meier methodSEER-Medicare dataProportional hazards modelDifferent treatment approachesHigh rateAdjuvant radiotherapyTreatment armsSurvival outcomesGleason scoreTumor stageClinical guidelinesHigh risk
2013
Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score–Matched Analysis
Shao Y, Kim S, Moore D, Shih W, Lin Y, Stein M, Kim I, Lu-Yao G. Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score–Matched Analysis. European Urology 2013, 65: 693-700. PMID: 23759328, PMCID: PMC3825778, DOI: 10.1016/j.eururo.2013.05.023.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalCancer-specific survivalPrimary radical prostatectomyRadical prostatectomyRT groupRadiation therapyProstate cancerIntermediate-high riskRisk of PCSMCancer-specific mortalityEnd Results-MedicarePrimary radiation therapyPropensity-matched cohortLow-risk patientsPrimary treatment modalityLocalized prostate cancerProstate cancer patientsDevelopment of metastasesOnset of metastasisResidual confoundersHazard ratioMetastatic diseaseRisk patientsClinical courseSurveillance Epidemiology